› 6fa1

X-ray diffraction
1.97Å resolution

Function and Biology Details

Reaction catalysed: 
GTP + H(2)O = GDP + phosphate
Biochemical function:
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
hetero hexamer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-133992 (preferred)
Entry contents:
3 distinct polypeptide molecules
Macromolecules (3 distinct):
GTPase KRas, N-terminally processed Chain: B
Molecule details ›
Chain: B
Length: 173 amino acids
Theoretical weight: 19.7 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: P01116 (Residues: 1-169; Coverage: 89%)
Gene names: KRAS, KRAS2, RASK2
Sequence domains: Ras family
Structure domains: P-loop containing nucleotide triphosphate hydrolases
GTPase KRas, N-terminally processed Chains: A, C, D, F
Molecule details ›
Chains: A, C, D, F
Length: 172 amino acids
Theoretical weight: 19.57 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: P01116 (Residues: 1-167; Coverage: 88%)
Gene names: KRAS, KRAS2, RASK2
Sequence domains: Ras family
Structure domains: P-loop containing nucleotide triphosphate hydrolases
GTPase KRas, N-terminally processed Chain: E
Molecule details ›
Chain: E
Length: 173 amino acids
Theoretical weight: 19.69 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: P01116 (Residues: 1-169; Coverage: 89%)
Gene names: KRAS, KRAS2, RASK2
Sequence domains: Ras family
Structure domains: P-loop containing nucleotide triphosphate hydrolases

Ligands and Environments

3 bound ligands:
Ligand MG 6 x MG
Ligand GNP 6 x GNP
Ligand D2Z 3 x D2Z
1 modified residue:
Ligand CSO 5 x CSO

Experiments and Validation Details

Entry percentile scores
X-ray source: DIAMOND BEAMLINE I02
Spacegroup: P212121
Unit cell:
a: 63.61Å b: 118.6Å c: 156.61Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.182 0.181 0.207
Expression system: Escherichia coli

Quick links

Citations

23 review citations

RAS-targeted therapies: is the undruggable drugged?
Moore et al. (2020)
22 more

4 mentions without citation

RAS Nanoclusters: Dynamic Signaling Platforms Amenable to Therapeutic Intervention.
Van et al. (2021)
3 more